

Fanvestments Corporation
Global Investments - Global Returns
Invest today, Build Wealth Forever

FVAM Fund Quarterly Portfolio Report
Q3 - 2024

Fanvestments Private Diversified Alternative Investment Fund (FVAM)

This Report describes the Fanvestments Private Alternative Investment Fund (the "Fund", "FVAM"). Fanvestments Corporation (the "Management"), a Rhode Island S-Corporation, serves as the Fund's Management Business. The following summary highlights information about the fund, during the 3rd & 4th Quarter of 2024, and info about the fund's investment strategy and expectations. Except where the context otherwise requires or indicates, in this report, (i) "Fanvestments," "the Business," "we," "us", "Firm", "management" and "our" refer to Fanvestments Corporation and/or owner, and its Primary offering, with respect to FVAM, a Private Alternative Investment Fund, referred to as "the Fund", "the portfolio", or "FVAM".

Contact and Social Media:

Fanvestments, Corporation

Matthew Fanning – Owner / Founder / CIO / Fund Manager

mfanning@fanvestments.com

www.fanvestments.com

Twitter: @fanvestments

facebook.com/fanvestments

Instagram: @fanvestments

PRINCIPAL INVESTMENT STRATEGY

The FVAM Fund consists of a diversified portfolio primarily focused on investing long within individual stocks & ETFs, "Equity long-bias", with small exposure towards hedging, as well as occasional exposure between commodities, fixed income and currencies. FVAM has a dual goal of capital appreciation AND preservation, looking for strong returns while applying a layer of defense to handle all types of economic and global financial cycles and market volatility. The fund applies multiple strategies, from fundamental research looking at earnings, revenue, growth rates, and valuation, to analyzing historical data and projecting future expectations. Combining fundamentals with technical analysis ("technical"), studying charts and price action for trends & patterns, as well as trend change, price and timeframe analysis, overbought and oversold indicators, and volume spikes leading to capitulation. The macro environment is very important as well, and will overlay macro research on top of other research and overall portfolio analysis. Other strategies, more of a focus within a sector, such as biotech, looking for companies that are trying to find cures/preventions for major diseases. Within Technology, to find innovation helping to disrupt and shape the future, such as AI, Big Data, Cloud, Security, Analytics, FinTech (financial technology). Price and Returns will always trump timeframes, "PriceFrame", being a far more important metric than timeframe, but the fund does expect to hold most core investments for multiple years, mid-to-long term.

The Fund is actively-managed with a blended investment style, looking for Growth at a great Value, Growth-on-Sale, utilizing more of a "buy the blood" strategy, buy low-sell high, as a fundamental mindset. The fund will also seek to find opportunities within event-driven strategies, such as potential buy-outs/mergers, FDA approvals, momentum and fund flows, as well as unusual options action. Part of the investment style is to bring together a diversified multi-asset "401k retirement" portfolio approach, combined with hedge fund, institutional style investment involving individual stock picking alongside minimal hedging against general market risk, as well as having low market correlation producing independent fund-specific returns. Only on a limited basis, and kept to very small exposure at most times, the fund does use multiple hedging strategies to protect from general stock market volatility, as well as downside risk within individual positions, or macro issues such as economic cycles, recessions, geopolitics. Currently any short exposure in the fund utilizes options vs outright selling short, such as index/ETF options, VIX (volatility) options, positional & sector hedges. Overall hedging exposure is kept low, utilizing more of a hedge by allocation strategy, such as Diversification and Position sizing, asset allocation management, always monitoring positional exposure relative to the risk of that position and overall portfolio size. As well as other portfolio management strategies such as performance monitoring and risk management, constantly studying fund volatility and day-to-day performance statistics.

The FVAM fund, is designed to be an all-weather style fund, "all-markets", meaning the fund can navigate through all types of economic and market cycles, taking advantage of the upside and withstanding periods of major market selloffs. FVAM is not a "thematic" fund, and its diversified, risk-sensitive strategies are built to suit investors of all-ages From the start, the fund always had intention to relate to the "conservative" retiree investor, where this group, at least to me, seems to giving up an extreme amount of capital growth in the years where it's needed most. FVAM is built to be worthy of a large portion of an overall portfolio, to pair perfectly alongside something like a 60-40 style strategy, and is built to be a forever investment. Since FVAM is not intending to mirror, or match the assets or performance of any other index or ETF, the fund's performance will not have any intention to directly match the performance of any other investment vehicle, ETF, or Index or have the same timing as the overall markets, "market neutral". FVAM's intent is to have created its own unique investment vehicle, with individual assets selected by Fanvestments Management, reduced market correlation, and less volatility vs market indices. Although compared to the S&P 500, this is not the fund's true benchmark, as the index is strictly a US large-cap index. FVAM is diversified among multiple market caps and sectors, multiple strategies, and has international exposure. Utilizing a dynamic and perpetually improving investment strategy combining increased Portfolio Quality, constant Portfolio analysis, non-stop financial market study, risk and allocation management, along with relentless analysis of performance metrics, statistics, with the goal of perpetual improvement. Matching up technical analysis for timing with Fundamental analysis for valuation, and overlaying Macro environment research to help find Global trends and determine overall Market risk.

Make the Money - Make More Money, Don't lose the Money .

Q3 Highlights



For the 3rd Quarter of 2024, the FVAM fund finished strong, with a +7.2% return. The fund was up 3.5% in July, down -1.3% in August, and up 5.1% in September. Year to date, at the end of Q3, FVAM was up just under +10%. On a relative basis for the year thru the 3rd Quarter, based on an internal performance tracker of ~40 indexes/sectors, FVAM was outperforming less than half of the components, outperforming 12. In Q3, the Fund did Outperform the S&P 500 which was up 5.7%, also outperforming major bond funds like TLT and HYG, as well as, Barclay's overall hedge fund index, up 3.85% for Q3 and would guess much higher fees than FVAM, and slightly outperformed a 60/40-stocks/bonds portfolio. For Q3, the Dow Jones was up 8%, with the small cap etf IWM, up 9.3%. The ACWX etf, which tracks stocks around the world excluding the United States, was up 7.8%, w/the RSP (equal-weight SP500) up +8.9%. Cathie Wood's ARKK thematic growth & innovation fund, was up 9.6%. Although there is no attempt to match the performance or timing of the S&P 500, along with mixed-asset exposure, multi-cap and multi-strategy, risk mgmt & hedge/short exposure, lower risk & volatility, and with equity exposure around 80-90% of the fund, the fund's performance and volatility is analyzed against the index, an all-stock and strictly large-cap index. Other reference points, more relative and important benchmarks for the fund, are Warren Buffett's Berkshire Hathaway, as well as SPLV, which is the S&P 500 Low Volatility etf. A less volatile alternative to the SP500 is a major goal/focus of the FVAM fund, making the SPLV a top benchmark for the fund. Using the BRK/b shares, Berkshire was up 12.7% for the 3rd quarter, w/SPLV up 10%. Through November '24, BRKb was up 31%, with the SPLV up +18%. FVAM rose 17% in the same timeframe, having a slow start to the year in January, up 21% since February.

The fund's YTD top performing investments at the end of 3rd quarter, best performers first, were Vertiv (VRT), Gilead (GILD), Amazon (AMZN), Microstrategy (MSTR), and Tesla (TSLA) as the top 5. Following them up was Disney (DIS), Grayscale Ethereum (ETHE), Novo Nordisk (NVO), Kraneshares China Internet (KWEB), and Spdr Biotech (XBI) rounding out the top 10. Of those top 10; MSTR, DIS, ETHE, NVO, KWEB, and XBI have all been sold-in-full sold, all for gains. MSTR the best performer of those 6, and remains 4th best position YTD, and still left some money on the table. Novo was one of the best sales of the year. Fund started buying NVO back in October '23, and continued to buy thru the quarter, average price in the high 90s. Started selling most of the position in July '24, sold-in-full by late August, avg. price ~135. NVO stock hit a top late June ~\$148, and has gone straight down since, down another 17% recently, falling down to \$85. Amazon remains a core-position, running between 10-12% of overall fund, and still have full conviction Amazon will continue to be a secular winner. Vertiv, Gilead, and Tesla also remain core positions. Fund bought/initiated positions in Albemarle (ALB), Genius Sports (GENI), Micron (MU), and bought back into Nvidia (NVDA). Looking further into Amazon, the fund's largest and what I call a "super-core" position. Fund started buying AMZN back in January '23 in the low 100s, w/some level of "trading around position", buying/selling small due to price action or position size/risk mgmt. As of Dec '24, fund has an avg price ~145, stock currently @ \$226, funds 2nd best performer YTD. In '25, looking for 18% sales growth, with '25 EPS growth of 26% y-o-y. Would get '25 revenue up to \$755 Billion, and '25 eps up to \$7. 1-2 year target @ \$305 using 4.2x '25 sales, or a \$3.2Trillion market cap, currently amazon sits at 3.9x sales. Higher-end, could see a peg of 2 (curr. 1.8) or 52x '25 EPS of \$7, gets the stock to \$364. Can read more about Amazon here: [Amazon Q3 '24](#)



Looking into Q4 2024, new positions were initiated in JD.com (JD), ELF Beauty (ELF), Boeing (BA), and ASML (ASML). Fund added to Albemarle (ALB), Osprey Solana (OSOL). MSTR was bought mostly in early August in the 130s, selling most ~250, left some on the table there but this stock is just insanely volatile, also fund's 4th best position YTD. Still one of the best levered ways to get exposure to Bitcoin, the fund does own BITU, another levered play on bitcoin, as well as solana via OSOL. Positions in XBI (biotech), AMD, and KWEB (china internet) were sold-in-full. Took a loss in AMD, but did sell before another 35% selloff in the stock. Small gains for XBI, better gains for KWEB, fund's 11th best pos. Ytd. Looking further into core-position ASML, quickly the fund's 2nd largest position, almost 7%. Fund started buying ASML mid-November, avg. price ~\$690, after the stock sold off from highs above \$1100. ASML is not just the key ingredient in building the world's most advanced chips, one of few holding a 90% market share, as the world's largest supplier of photolithography machines. ASML serves clients like TSMC, Samsung, and Intel. For just an example, the world needs Ai, Ai needs Nvidia, Nvidia needs Taiwan Semi, Taiwan Semi needs ASML, aka - Ai needs ASML. For 2025, looking for 25% sales growth with EPS growth of 45%+. Would get '25 revenue up to \$35 Billion, and '25 eps up to \$28. 1-2 year target @ \$1250, \$500b market cap, ~75% upside. Can read more about ASML here: [ASML Investor Relations](#) .

Below shows reporting created & analyzed within Data Analytics software, Tableau Software, which has data integration into the fund's internal database/spreadsheets. (*Portfolio Data as-of Oct 2024)

High Level allocation heat map and pie chart:




Below shows the further breakdown of only the fund's equity/option exposure.




Performance Analysis: Analyzing the breakdown of the Fund's performance, as well as comparisons to other investment vehicles/index, such as the S&P 500, \$BRK-b (Warren Buffett's 'Berkshire Hathaway'), ACWX which tracks Global Markets minus the US (World x-US), and the Russell 2000 small cap index (\$IWM)


FVAM fund, 3rd Quarter 2024




FVAM fund, cumulative return year-to-date




FVAM fund (blue) vs SPX (S&P 500, orange), performance since July 1st




FVAM fund (blue) vs SPLV (S&P 500 low-volatility, orange), cumulative, YTD thru Nov.




FVAM fund (green, left) vs BRK/b (blue, right), YTD thru November '24, Weekly
 (\$BRK-B : Berkshire Hathaway B-shares)




FVAM fund (green, left) vs BRK/b (blue, right), Q3 2024, Weekly




FVAM vs BRK/b and relative return (FVAM vs BRK/b), 1yr
 (excess: positive = outperformance, negative = underperformance)




FVAM vs BRK/b and relative return (FVAM vs BRK/b), Q3 2024
 (excess, positive = outperformance, negative = underperformance)




FVAM (Green) vs IBB (BioTech Index Fund) vs BRK/b (Berkshire Hathaway) vs QQQ (Nasdaq-100), Q3 '24




FVAM (green) vs S&P500 vs BRK/b (Berkshire Hathaway) vs ACWI (World Index) vs IBB (BioTech Index Fund) vs LQD (Bonds) vs EEM (Emerging Markets) vs QQQ (Nasdaq), July thru Nov.




FVAM vs SPX and relative return (FVAM vs SPX), Q3 - 2024, weekly
 (*excess return shows relative performance)




FVAM vs SPX and relative return (FVAM vs SPX), YTD thru November




FVAM vs IWM (small caps) vs IBB (biotech) vs SPX (S&P 500) vs ACWI (world index) vs ACWX (world x-US) vs LQD (bonds), Weekly, Q3




FVAM vs S&P 500 (\$SPX) vs Berkshire Hathaway (\$BRK/b) vs \$SPLV (S&P500 Low Volatility etf) vs \$ACWX (World Index x-US etf), Weekly, Q3




FVAM (green) vs EEM (Emerging Markets) , from Jan 2023




FVAM (green) vs LQD (Investment Grade Corporate Bonds), since Jan 2023




S&P 500 (orange) vs ACWX (blue, World Index minus U.S.), Q3 2024, Weekly



FVAM vs ACWI (World Index), with Relative Return (excess return), since YTD '24




FVAM (green) vs ACWX (World Index minus USA, blue) vs S&P 500, 1-year, monthly returns



Reference 1: FVAM Fund Performance Stats (showing view of June 2024, FVAM vs SPX, Statistics)

The data below, displaying just September 2024 in this example, shows performance statistic data maintained daily, showing the FVAM fund vs the S&P 500, even though FVAM is not trying to match or mimic the actual underlying stocks, within the S&P 500, or match the performance of the index. Data shows performance for FVAM, performance for the S&P 500 (\$SPX), as well as relative performance and mathematical statistics (showing risk & volatility). The chart displays daily performance for both FVAM (green) and SPX (blue). Another very important factor for FVAM is to be less volatile than the SPX, which is being analyzed using Statistics, such as Standard Deviation (SDDEV). Excess Return shows relative performance between FVAM and \$SPX (outperformance positive, or underperformance negative). Index C shows plus or minus on a progressive (rolling) basis through the month. The "match (golf)" column also shows that progressive relative performance, but for larger outperformance or underperformance, using a 50bp (+/- 0.5%) differential.

September 2024



*SPX (S&P500 index), BRK/B (Berkshire Hathaway) and any other index/fund/investment vehicles' performance using internal data tracking and data from multiple public internet sources, "non-official" data only.

Heat Map for the Dow Jones Index, showing each stock within that index/sector along with its relative size and weight compared to the overall index (**larger the block size the larger percentage that stock makes up within the index**). The colors represent gains or losses for that current day. (*as of early December 2024)

